Krystal Biotech, Inc. (FRA:4KB)

Krystal Biotech Statistics

Total Valuation

Krystal Biotech has a market cap or net worth of EUR 6.50 billion. The enterprise value is 5.69 billion.

Market Cap	6.50B
Enterprise Value	5.69B

Important Dates

The last earnings date was Tuesday, February 17, 2026.

Earnings Date	Feb 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	29.23M
Shares Outstanding	n/a
Shares Change (YoY)	+0.71%
Shares Change (QoQ)	+1.40%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	23.01M

Valuation Ratios

The trailing PE ratio is 37.24 and the forward PE ratio is 31.96.

PE Ratio	37.24
Forward PE	31.96
PS Ratio	19.60
PB Ratio	6.25
P/TBV Ratio	6.25
P/FCF Ratio	40.37
P/OCF Ratio	37.97
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 40.71, with an EV/FCF ratio of 35.38.

EV / Earnings	32.63
EV / Sales	17.23
EV / EBITDA	40.71
EV / EBIT	41.58
EV / FCF	35.38

Financial Position

The company has a current ratio of 9.95, with a Debt / Equity ratio of 0.01.

Current Ratio	9.95
Quick Ratio	9.28
Debt / Equity	0.01
Debt / EBITDA	0.06
Debt / FCF	0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 18.91% and return on invested capital (ROIC) is 39.46%.

Return on Equity (ROE)	18.91%
Return on Assets (ROA)	8.44%
Return on Invested Capital (ROIC)	39.46%
Return on Capital Employed (ROCE)	13.10%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.12M
Profits Per Employee	591,371
Employee Count	295
Asset Turnover	0.33
Inventory Turnover	0.69

Taxes

Income Tax	-13.08M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +49.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+49.53%
50-Day Moving Average	223.88
200-Day Moving Average	159.40
Relative Strength Index (RSI)	44.52
Average Volume (20 Days)	14

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.76

Income Statement

In the last 12 months, Krystal Biotech had revenue of EUR 331.42 million and earned 174.45 million in profits. Earnings per share was 5.83.

Revenue	331.42M
Gross Profit	311.79M
Operating Income	137.37M
Pretax Income	161.37M
Net Income	174.45M
EBITDA	138.76M
EBIT	137.37M
Earnings Per Share (EPS)	5.83

Balance Sheet

The company has 705.03 million in cash and 7.95 million in debt, with a net cash position of 806.15 million.

Cash & Cash Equivalents	705.03M
Total Debt	7.95M
Net Cash	806.15M
Net Cash Per Share	n/a
Equity (Book Value)	1.04B
Book Value Per Share	35.58
Working Capital	784.98M

Cash Flow

In the last 12 months, operating cash flow was 171.08 million and capital expenditures -10.18 million, giving a free cash flow of 160.90 million.

Operating Cash Flow	171.08M
Capital Expenditures	-10.18M
Free Cash Flow	160.90M
FCF Per Share	n/a

Margins

Gross margin is 94.08%, with operating and profit margins of 41.45% and 52.64%.

Gross Margin	94.08%
Operating Margin	41.45%
Pretax Margin	48.69%
Profit Margin	52.64%
EBITDA Margin	41.87%
EBIT Margin	41.45%
FCF Margin	48.55%

Dividends & Yields

Krystal Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.71%
Shareholder Yield	-0.71%
Earnings Yield	2.69%
FCF Yield	2.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Krystal Biotech has an Altman Z-Score of 27.2 and a Piotroski F-Score of 6.

Altman Z-Score	27.2
Piotroski F-Score	6